Literature DB >> 18448095

Differential sensitivity of colorectal cancer cell lines to artesunate is associated with expression of beta-catenin and E-cadherin.

Lin-Na Li1, Hua-Dong Zhang, Shou-Jun Yuan, De-Xuan Yang, Lin Wang, Zhi-Xian Sun.   

Abstract

Artesunate, a remarkable antimalarial agent, also reveals profound cytotoxic activity. In the present investigation, we compared the anticancer effects of artesunate on three colorectal cancer cell lines and analyzed the relationship between drug sensitivity and malignant phenotype of the tumor cells. The findings are as follows: poorly-differentiated was colorectal cancer cell line CLY showing nuclear beta-catenin accumulation and loss of E-cadherin; moderately-differentiated were Lovo cells with cytoplasmic distribution of the two proteins; and well-differentiated were HT-29 cells with membranous localization of them. Also, both in vitro and in vivo, poorly- or moderately-differentiated CLY and Lovo were more susceptible to artesunate treatment than well-differentiated HT-29. Furthermore, the sensitive response of CLY and Lovo to artesunate was associated with membranous translocation of beta-catenin and increased expression of E-cadherin, which indicated the inhibition of hyperactive Wnt signaling pathway and the reversion of the epithelial to mesenchymal transition, respectively. Due to the vital roles of Wnt pathway and the epithelial to mesenchymal transition in tumor differentiation, we thought artesunate could promote the re-differentiation and apoptosis of colorectal cancer cells by inhibition of hyperactive Wnt pathway and reversion of the epithelial to mesenchymal transition.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18448095     DOI: 10.1016/j.ejphar.2008.03.041

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  11 in total

Review 1.  β-catenin/TCF-1 pathway in T cell development and differentiation.

Authors:  Jian Ma; Ruiqing Wang; Xianfeng Fang; Zuoming Sun
Journal:  J Neuroimmune Pharmacol       Date:  2012-04-27       Impact factor: 4.147

2.  Artesunate inhibits cell proliferation and decreases growth hormone synthesis and secretion in GH3 cells.

Authors:  Zhi-Gang Mao; Jing Zhou; Hui Wang; Dong-Sheng He; Wei-Wei Xiao; Gui-Zhi Liao; Lu-Bin Qiu; Yong-Hong Zhu; Hai-Jun Wang
Journal:  Mol Biol Rep       Date:  2012-01-05       Impact factor: 2.316

Review 3.  Development of artemisinin compounds for cancer treatment.

Authors:  Henry C Lai; Narendra P Singh; Tomikazu Sasaki
Journal:  Invest New Drugs       Date:  2012-08-31       Impact factor: 3.850

4.  Artesunate altered cellular mechanical properties leading to deregulation of cell proliferation and migration in esophageal squamous cell carcinoma.

Authors:  Ruyi Shi; Heyang Cui; Yanghui Bi; Xun Huang; Bin Song; Caixia Cheng; Ling Zhang; Jing Liu; Chanting He; Fang Wang; Zhiwu Jia; Bin Yang; Juan Wang; Jinyao Dong; Zhijie DU; Shuaishuai Xiao; Yongping Cui; Xiaolong Cheng
Journal:  Oncol Lett       Date:  2015-02-24       Impact factor: 2.967

5.  Tumor-Stromal Interactions Influence Radiation Sensitivity in Epithelial- versus Mesenchymal-Like Prostate Cancer Cells.

Authors:  Sajni Josson; Starlette Sharp; Shian-Ying Sung; Peter A S Johnstone; Ritu Aneja; Ruoxiang Wang; Murali Gururajan; Timothy Turner; Leland W K Chung; Clayton Yates
Journal:  J Oncol       Date:  2010-07-29       Impact factor: 4.375

Review 6.  Antitumor activity of artemisinin and its derivatives: from a well-known antimalarial agent to a potential anticancer drug.

Authors:  Maria P Crespo-Ortiz; Ming Q Wei
Journal:  J Biomed Biotechnol       Date:  2011-11-22

7.  Lower Expression of Gelsolin in Colon Cancer and Its Diagnostic Value in Colon Cancer Patients.

Authors:  Zhuoyu Chen; Kaifei Li; Xiaofeng Yin; Haixia Li; Yao Li; Qiong Zhang; Haifang Wang; Yurong Qiu
Journal:  J Cancer       Date:  2019-01-30       Impact factor: 4.207

Review 8.  Artemisinins as a novel anti-cancer therapy: Targeting a global cancer pandemic through drug repurposing.

Authors:  Yolanda Augustin; Henry M Staines; Sanjeev Krishna
Journal:  Pharmacol Ther       Date:  2020-10-16       Impact factor: 12.310

Review 9.  Repurposing Artemisinin and its Derivatives as Anticancer Drugs: A Chance or Challenge?

Authors:  Zhaowu Ma; Clariis Yi-Ning Woon; Chen-Guang Liu; Jun-Ting Cheng; Mingliang You; Gautam Sethi; Andrea Li-Ann Wong; Paul Chi-Lui Ho; Daping Zhang; Peishi Ong; Lingzhi Wang; Boon-Cher Goh
Journal:  Front Pharmacol       Date:  2021-12-31       Impact factor: 5.810

10.  Cyclic AMP efflux inhibitors as potential therapeutic agents for leukemia.

Authors:  Dominique R Perez; Yelena Smagley; Matthew Garcia; Mark B Carter; Annette Evangelisti; Ksenia Matlawska-Wasowska; Stuart S Winter; Larry A Sklar; Alexandre Chigaev
Journal:  Oncotarget       Date:  2016-06-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.